Psybio Therapeutics Corp Stock Current Liabilities

PSYBF Stock  USD 0.0001  0.00  0.00%   
PsyBio Therapeutics Corp fundamentals help investors to digest information that contributes to PsyBio Therapeutics' financial success or failures. It also enables traders to predict the movement of PsyBio Pink Sheet. The fundamental analysis module provides a way to measure PsyBio Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PsyBio Therapeutics pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

PsyBio Therapeutics Corp Company Current Liabilities Analysis

PsyBio Therapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.

Current Liabilities

 = 

Payables

+

Accrued Debt

More About Current Liabilities | All Equity Analysis
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
Competition

In accordance with the recently published financial statements, PsyBio Therapeutics Corp has a Current Liabilities of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.

PsyBio Current Liabilities Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PsyBio Therapeutics' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of PsyBio Therapeutics could also be used in its relative valuation, which is a method of valuing PsyBio Therapeutics by comparing valuation metrics of similar companies.
PsyBio Therapeutics is currently under evaluation in current liabilities category among its peers.

PsyBio Fundamentals

About PsyBio Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze PsyBio Therapeutics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PsyBio Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PsyBio Therapeutics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in PsyBio Pink Sheet

PsyBio Therapeutics financial ratios help investors to determine whether PsyBio Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PsyBio with respect to the benefits of owning PsyBio Therapeutics security.